Tag: KDC-MN-209

  • Duloxetine

    Serotonin-norepinephrine reuptake inhibitor

    A balanced-affinity SNRI distinguished by approval for chronic pain and diabetic peripheral neuropathy in addition to depression.

    Abstract

    Duloxetine ((S)-N-methyl-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propan-1-amine; CAS 116539-59-4; molecular formula C18H19NOS; molecular weight 297.41) is a balanced-affinity SNRI developed at Eli Lilly and approved by the FDA in 2004 under the trade name Cymbalta. SERT (Ki approximately 0.8 nM) and NET (Ki approximately 7.5 nM) affinities are both nanomolar, with a SERT/NET ratio of roughly 10, more balanced than venlafaxine (ratio approximately 30). The compound exhibits weak DAT inhibition (Ki approximately 240 nM) of marginal clinical relevance. Plasma half-life is approximately 12 hours; metabolism is via CYP1A2 (primary) and CYP2D6 (secondary). The compound is itself a moderate CYP2D6 inhibitor, producing relevant interactions with TCAs, antipsychotics, and tamoxifen. Approved indications include major depressive disorder, generalized anxiety disorder, fibromyalgia, diabetic peripheral neuropathic pain, and chronic musculoskeletal pain. The pain indications reflect the noradrenergic component’s role in descending pain modulation. Used as the canonical balanced SNRI in mechanism studies and as a reference compound for descending pain modulation research.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.